1

Future of Glycoengineering and Quality-by-Design (QbD) in CHO Cell-Based Biopharmaceutical Production, 2025–2032.

News Discuss 
A new industry analysis confirms that the global Chinese Hamster Ovary (CHO) Cells Market is experiencing robust expansion, driven primarily by the escalating demand for high-quality recombinant protein production and complex biologic drugs. CHO cells are the cell line of choice for producing nearly 70% of all therapeutic proteins, including monoclonal antibodies (mAbs), and thus ... https://shashikant873.livejournal.com/3767.html

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story